Marin & Murphy

Ozempic (GLP-1) — Arkansas Litigation

The Ozempic Litigation, Explained

Two consolidated federal proceedings, a September 2026 expert hearing, and state deadlines that vary — here is where the litigation stands.

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.

Marin & Murphy is not licensed in Arkansas; details below.
Matthew T. Marin & Stefanie A. Murphy

Partners

Matthew T. Marin & Stefanie A. Murphy

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state. Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber. Whether any individual has a claim depends on their medical records and the law of their state. The information below covers the litigation itself.

Arkansas produces fewer GLP-1 lawsuits than its neighbors — its Medicaid program reported one of the smaller prescription volumes in the country — but the ones it does produce follow the national route: MDL 3094 for stomach injuries, MDL 3163 for NAION vision loss, both before Judge Karen S. Marston in the Eastern District of Pennsylvania. What the cases allege is set out on our page about the stomach-paralysis and vision-loss claims.

Marin & Murphy Law Firm is a national mass tort and personal injury law firm with offices in Rhode Island and South Carolina, representing injured people and families nationwide. The firm’s mass-tort practice is directed from its Charleston, South Carolina office. Where a matter arises in a state in which our attorneys are not admitted, we work with lawyers licensed in that state. Marin & Murphy Law Firm is not licensed to practice law in Arkansas. This page is provided for informational purposes and does not constitute an offer to represent any Arkansas resident. The firm does not accept Arkansas legal matters; inquiries from Arkansas residents are referred to attorneys licensed in Arkansas.

4,082 cases
MDL 3094 (stomach injuries), Nov 2026
278 cases
MDL 3163 (NAION), Nov 2026
0 settlements
no case has resolved

Eastern or Western District, same result

Arkansas has two federal districts — the Eastern and Western Districts of Arkansas — and a GLP-1 case filed in either is transferred by the Judicial Panel on Multidistrict Litigation to the consolidated proceedings: MDL 3094 (stomach injuries) or MDL 3163 (NAION), before Judge Karen S. Marston in the Eastern District of Pennsylvania. November 2026 JPML count: 4,082 cases and 278 cases respectively. Verdicts so far: none. Settlements: none.

An Arkansas case, up close: three drugs, one filing

There’s no official state-by-state tally for these dockets, so instead of estimating we track actual Arkansas filings from the court record. On December 18, 2025, an Arkansas resident filed King v. Novo Nordisk, No. 2:25-cv-07161 (E.D. Pa.) — an 11-page short form complaint on the public docket, direct-filed into MDL 3094 with the Eastern District of Arkansas designated as its Original Venue — the home court the case is set up to return to for trial, subject to the challenges the Direct Filing Order preserves, naming all four GLP-1 manufacturer defendants. Direct filing meant no wait for a JPML transfer order; the home district stayed on file as its Original Venue for any later transfer out.

What makes it worth reading closely is the product history: the filing alleges Mounjaro use across two separate periods in 2021 and 2022, Wegovy from August to November 2021, and semaglutide use again in December 2023 and October 2024 — three products, four discrete windows. It checks a gallbladder injury, treated by laparoscopic cholecystectomy, from the form’s list, and adopts eight of the master complaint’s sixteen counts, led by the failure-to-warn core through Count VI, plus Count XI and negligent undertaking. It leaves the statutory counts unchecked; the master complaint’s state-law inventory pleads Arkansas’s consumer-protection statute for plaintiffs who assert it; Arkansas is not a product-liability-act state, so the common-law counts carry the case. Deemed answered and denied on filing, like every MDL case, with no individual answer from any defendant appearing on the docket. The form’s fields are walked through on our short form complaint page.

Standard cautions: one plaintiff’s pleading, public record, its allegations unproven and disputed. A four-window product history like this is not unusual in the record, but it is not a predictor of any other Arkansas case either. The deadline it beat is covered next.

Three years — but read the fine print

Arkansas allows three years for most personal-injury claims, but its accrual rules run narrower than many states’: depending on the claim, the clock can start at the injury rather than at your discovery of it. The deadline section below carries the citations; an early dates review carries the protection.

Small numbers, big context: Arkansas data

The federal data shows a small but real footprint: at least 2,344 Ozempic prescriptions through Arkansas Medicaid in 2024, with at least 691 more for Mounjaro and 471 for Trulicity (CMS State Drug Utilization Data). The context is what stands out — CDC 2023 age-adjusted rates of 13.1% diabetes and 40.9% obesity among Arkansas adults rank among the nation’s highest. Counts are floors: Medicaid only, small cells suppressed.

Medication AR Medicaid prescriptions (2024) Amount reimbursed
Ozempic (semaglutide) 2,344 $2,218,358
Trulicity (dulaglutide) 471+ $449,260+
Mounjaro (tirzepatide) 691+ $724,778+
Wegovy (semaglutide) suppressed in federal data (small counts)
Rybelsus (semaglutide) suppressed in federal data (small counts)
Sources: CMS State Drug Utilization Data 2024, data.medicaid.gov (accessed Aug 21, 2026); CDC U.S. Chronic Disease Indicators, data.cdc.gov (2023, age-adjusted). Counts are floors: Medicaid claims only, and cells with small counts are suppressed in the federal dataset.

Arkansas deadlines: the statutory detail

Arkansas allows three years for injury and product-liability claims, measured from the date the death, injury, or damage occurs (Ark. Code Ann. §§ 16-56-105, 16-116-203); Arkansas courts apply discovery-based timing only narrowly, so treat the injury date as the safe starting point. A wrongful-death claim must be brought within three years of death by the personal representative, or by the heirs at law if there is none (§ 16-62-102). Federal cases filed in any of Arkansas’s federal districts are transferred to the consolidated GLP-1 proceedings for pretrial work. Exceptions exist on both sides of these rules — your actual deadline emerges only from a review of your own dates.

Nearby: Ozempic lawsuit information for Tennessee, Mississippi, Oklahoma, Alabama, Kentucky, and Kansas — or browse every state.

Who may qualify

  • Stomach injuries (gastroparesis or gastric obstruction): use of brand-name Ozempic, Wegovy, or Rybelsus (not compounded or generic semaglutide); a diagnosis confirmed by objective testing such as a gastric emptying study, made while taking the medication or within about 30 days of stopping; a related emergency-room visit or hospital admission; and a diagnosis made before December 31, 2024.
  • NAION (sudden optic-nerve vision loss): use of brand-name Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, or Zepbound; an actual NAION diagnosis made during or after use; and some degree of permanent vision impairment.
  • Criteria evolve, and near-miss situations are often worth reviewing with a lawyer licensed in your state.

Common questions

How widespread is GLP-1 use in Arkansas?

Arkansas Medicaid’s reported GLP-1 volume is modest — over 3,000 prescriptions in 2024 (CMS data), most of them Ozempic — but Medicaid is one payer among many in a state where the CDC (2023) reports 13.1% adult diabetes and 40.9% obesity, both near the top nationally. The exposure base is much bigger than the Medicaid number.

Do Arkansas Ozempic cases stay in Arkansas?

They pass through and move on: filings from the Eastern and Western Districts of Arkansas are consolidated by the JPML into MDL 3094 or MDL 3163 in the Eastern District of Pennsylvania for pretrial work, with remand to Arkansas available for cases that don’t resolve there.

Is there an Ozempic lawsuit in Arkansas?

Yes. Arkansans’ claims are folded into the consolidated national dockets — MDL 3094 for stomach injuries and MDL 3163 for NAION — both pending before Judge Karen S. Marston in the Eastern District of Pennsylvania.

What is the deadline to file in Arkansas?

The period comes from Arkansas statute; the start date is the contested part, and Arkansas’s rules will not always wait for you to link the injury to the drug. Read the cited section below, then have a lawyer run your actual dates.

Has anyone received an Ozempic settlement?

No. As of November 2026 there are no settlements and no verdicts in any GLP-1 injury lawsuit. Anyone quoting settlement dollar amounts is speculating.

Do I sue my doctor?

No. These lawsuits are against the drug manufacturers — Novo Nordisk and Eli Lilly — not against your prescribing doctor or your pharmacy.

Sources
  • JPML MDL statistics report, November 2026 (MDL 3094; MDL 3163)
  • JPML Transfer Order, In re Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094 (Feb. 2, 2024)
  • JPML Transfer Order, MDL No. 3163 (Dec. 15, 2025)

No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone’s injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.

Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber.

Attorney Advertising.

This page is attorney advertising and is for informational purposes only; it is not legal or medical advice. Prior results do not guarantee a similar outcome. Contacting the firm does not create an attorney-client relationship.

The firm does not accept Arkansas legal matters; inquiries from Arkansas residents are referred to attorneys licensed in Arkansas.